2026-07-22 – Press Releases – www.prnewswire.com
Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva’s lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors SINGAPORE, July 22, 2026 /PRNewswire/ — Tikva Allocell Pte. Ltd. (“Tikva”), a biotechnology company…
